Belite Bio, Inc American Depositary Shares (BLTE) Financials
Key financial figures for Belite Bio, Inc American Depositary Shares (Q2 2026).
Belite Bio, Inc reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $28.4 million, or -$0.71 per share. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Belite Bio, Inc are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$28M
- EPS
- $-0.71
- Total Assets
- $792M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$28M | -$0.71 | ||
| Q1 FY2026 | $0 | -$27M | -$0.68 | $0 | |
| Q4 FY2025 | $0 | -$25M | -$0.72 | -$11K | |
| Q3 FY2025 | $0 | -$22M | -$0.65 | $0 | |
| Q2 FY2025 | $0 | -$16M | -$0.50 | $0 |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$78M | -$2.31 | -$37M | |
| FY2024 | $0 | -$36M | -$1.18 | -$29M | |
| FY2023 | $0 | -$32M | -$1.19 | -$30M |
Frequently asked questions
What was Belite Bio, Inc's revenue last quarter?
Belite Bio, Inc reported revenue of $0.00 for Q2 FY2026.
Is Belite Bio, Inc profitable?
Not in its most recent reported period. Belite Bio, Inc reported a net loss of $28.4 million for Q2 FY2026.
How many quarters of Belite Bio, Inc financials does SentiSense hold?
SentiSense holds up to forty quarters and twenty fiscal years of income statement, balance sheet and cash flow history for BLTE. The 5 most recent quarters are summarised above.
Full income statement, balance sheet and cash flow for Belite Bio, Inc American Depositary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.